Bis 5
Alternative Names: BIS-5; LNL-005Latest Information Update: 13 Jul 2023
Price :
$50 *
At a glance
- Originator L and L Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 12 Jul 2023 Phase-I clinical trials in Colorectal cancer in China (Parenteral) (L and L Biopharma pipeline, July 2023)
- 12 Jul 2023 Phase-I clinical trials in Colorectal cancer in USA (Parenteral) (L and L Biopharma pipeline, July 2023)
- 30 Jun 2022 Phase-I clinical trials in Non-small cell lung cancer (Second-line therapy or greater) (Parenteral) (L and L Biopharma pipeline,